P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS

Samankaltaisia teoksia

• P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS
  Tekijä: Ilaria Vigliotta, et al.
  Julkaistu: (2023-08-01)
• High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
  Tekijä: Marina Martello, et al.
  Julkaistu: (2024-11-01)
• Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients
  Tekijä: Enrica Borsi, et al.
  Julkaistu: (2024-04-01)
• The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases
  Tekijä: Ilaria Vigliotta, et al.
  Julkaistu: (2022-10-01)
• Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma
  Tekijä: Andrea Poletti, et al.
  Julkaistu: (2025-05-01)